TACROLIMUS AND PIMECROLIMUS
A challenge in designing this issue of Seminars in Cutaneous Medicine and Surgery was to collect and present a state of the art assessment of our knowledge of these medications for dermatologic use, while acknowledging that our communal experience with them is still fairly limited.
This article examines the pathophysiologic mechanisms involved in atopic dermatitis. An understanding of these mechanisms is critical for developing new treatment strategies for this increasingly common illness.
Tacrolimus (FK506) is a calcineurin inhibitor with potent immunomodulating properties, it has been marketed worldwide since 1993-1994 for the rejection of liver and kidney transplants (Prograf).
The ascomycin macrolactam derivative pimecrolimus (Elidel, SDZ ASM 981; Novartis Pharma AG, Basel Switzerland) is a cell-selective inhibitor of inflammatory cytokines specifically developed for the treatment of inflammatory skin diseases, such as atopic dermatitis, allergic contact dermatitis, irritant contact dermatitis, and plaque-type psoriasis.
In this article, we review the systemic and topical toxicities of these macrolide immunomodulators.